Anne Galy is currently head of Inserm Unit 951 at Genethon in Evry. She has received a Doctorate in Pharmacy and a PhD in Immunology at the University of Lyon France, respectively in 1985 and 1989. In the early 1990's, she trained in Palo Alto, California as a post-doctoral fellow at DNAX research institute (with H. SPits) and worked as a scientist at SySTEMix Inc. also in Palo Alto, prior to joining Wayne State University in Detroit, Michigan where, in 2001, she became a tenured Associate Professor at the School of Medicine and Barbara Ann Karmanos Cancer Institute. Dr. Galy was recruited at Inserm, the French National Medical Research Institute where she holds a permanent position as Director of Research.
Dr. Galy is expert in immunology and gene therapy. She was awarded the "Thermo Fischer Scientific" Biotherapy prize in 2009. She sits on the scientific editorial board of "Human Gene Therapy" and on the board of the French Society for Cell and Gene Therapy.
Dr. Galy's Inserm laboratory is affiliated with the Evry University and EPHE. The laboratory is situated within Genethon, a non-for profit institute dedicated to the treatment of rare diseases by cell and gene therapy.
Dr. Galy's laboratory is interested in the gene-modification of the immune and blood system for therapeutic applications.
Through a multi-disciplinary program established at Genethon, Dr. Galy is developing treatments for primary immune and blood genetic diseases by stable gene-modification of hematopoietic stem cells. Currently, international clinical trials are conducted to test a lentiviral vector for the gene therapy of Wiskott Aldrich Syndrome.
Dr. Galy's research team also conducts experimental research projects on the mechanisms of gene transfer in stem cells and on the control of immune responses induced by viral gene transfer, both at the level of innate immunity or for the purpose of inducing gene-specific immune tolerance.